All times are listed in CEST (Central European Summer Time)
Found 34 Presentations For Request "chen"
133MO - Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma
- Pei-Hsing Chen (Hsinchu City, Taiwan)
Abstract
Background
Recent lung cancer screening trials indicate that low-dose computed tomography (LDCT) has been successful in reducing mortality in high-risk patients. Nonetheless, the high frequency of false-positives leads to expense and possible harm, emphasizing the necessity for complementary biomarkers. To address this, we aimed to enhance the accuracy of lung cancer screening by utilizing a lung cancer-specific immunoassay panel for epigenetically modified nucleosomes in plasma to help differentiate between benign and malignant nodules.
Methods
During the years 2021 and 2022, a total of 806 individuals who had a positive result from LDCT screening and underwent surgery or biopsy were included in the study. Plasma samples from these participants were analyzed for nucleosomes containing histone modifications including H3K27Me3, H3K36Me3, or the H3.1 histone isoform by quantitative immunoassay (Nu.Q®, Belgian Volition SRL). Among these individuals, 648 were diagnosed with either lung cancer or a pre-cancerous lesion, while 158 were diagnosed with a benign lesion based on pathological reports. Logistic regression was used to analyze the assay data, and a simple algorithm was developed to predict whether a nodule was benign or malignant. The algorithm was created using samples collected in 2021 (n=561) as a training set and validated using samples collected in 2022 (n=245).
Results
The plasma epigenetic nucleosome assay for detecting lung cancer showed a diagnostic sensitivity of 92% and a specificity of 82% using a simple regression algorithm, trained on data from the 2021 group. The AUC for differentiating between cancerous and benign nodules was 88%. When the assay was applied to data from 2022, it achieved an AUC of 77% for distinguishing between cancer and benign nodules, with a sensitivity of 60% and a specificity of 84%. The validation test revealed that the algorithm correctly identified patients with stage I cancer and carcinoma in situ in 58% and 61% of cases, respectively.
Conclusions
This large validation study indicates that the epigenetic nucleosome assay has predictive, diagnostic, and prognostic value and could reduce the false-positive rate of LDCT.
Legal entity responsible for the study
The authors.
Funding
Belgian Volition.
Disclosure
P. Chen: Financial Interests, Institutional, Funding: volition. D. Pamart, T. Bygott: Financial Interests, Personal, Full or part-time Employment: Volition. M. Herzog: Financial Interests, Personal, Full or part-time Employment: Belgian Volition; Financial Interests, Personal, Stocks/Shares: VolitionRx; Non-Financial Interests, Member: ASCO. J. Micallef: Financial Interests, Personal, Officer, Chief Scientific Officer: VolitionRx Ltd; Financial Interests, Personal, Stocks/Shares: VolitionRx Ltd. J. Chen: Financial Interests, Institutional, Local PI: Volition. All other authors have declared no conflicts of interest.
Discussion
- All Speakers (Lugano, Switzerland)
When and why to test a patient with sarcoma for hereditary predisposition
- David Thomas (Sydney, Australia)
How to use radiology in patients with hereditary syndromes
- Christina Messiou (London, United Kingdom)
How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A surgeon’s perspective
- Sylvie Bonvalot (Paris, France)
How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist’s perspective
- Winette T. Van Der Graaf (Amsterdam, Netherlands)
How to treat sarcoma patients with a hereditary predisposition: A radiation oncologist’s perspective
- Beate Timmermann (Essen, Germany)
1512MO - Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)
- Chen Li (Shanghai, China)
Abstract
Background
The efficacy of standard perioperative chemotherapy for patients (pts) with localized resectable G/GEJ cancer still needs to be further improved. This ongoing multicentred, randomized, open-label, phase III study compared efficacy and safety of perioperative C plus R and chemo (SOXRC) versus chemo alone (SOX) in localized resectable G/GEJ adenocarcinoma.
Methods
Pts with T3-4aN+M0 were randomized 1:1 to SOXRC (C 200 mg IV D1 + R 250 mg PO QD D1-21 + oxaliplatin 130 mg/m2 IV D1 + S-1 PO BID D1-14, Q3W) or SOX for 3 cycles pre/post D2 surgery, then R plus C (SOXRC) or S-1 (SOX) up to 17 cycles per investigator’s choice. Stratification was by tumour location (GEJ vs G) and bulky N (yes vs no). Blinded independent review committee (BIRC) assessed pathological complete response (pCR, ypT0) and investigators assessed EFS were primary endpoints. The secondary endpoints were major pathological response (MPR), total pCR (ypT0N0), R0 resection, DFS and OS. The planned sample size was 512 pts. The main analysis of pCR would be conducted after the first 360 randomized pts had the opportunity for D2 surgery.
Results
Of the first 360 randomized pts (SOXRC n=180; SOX n=180), 71.4% had gastric cancer and 28.6% had GEJ cancer; 66.7% had T4 and 100% had N+ with balanced baseline between arms. 179 pts received neoadjuvant therapy, 164 completed all neoadjuvant therapy and 155 underwent surgery (SOXRC); 177, 169 and 156 did the same (SOX). In the ITT population, BIRC-assessed pCR was 18.3% (95% CI 13.0-24.8) for SOXRC and 5.0% (95% CI 2.3-9.3) for SOX, with a statistically significant improvement of 13.7% (95% CI 7.2-20.1, p<0.0001); MPR was 51.1% vs 37.8%; tpCR was 16.7% vs 4.4%. In the surgery set, R0 resection was 98.7% (SOXRC) vs 94.2% (SOX). Surgical complications occurred at rates of 27.7% (SOXRC) and 30.1% (SOX). Preoperative grade ≥3 treatment-emergent adverse events occurred at rates of 36.3% (SOXRC) and 16.3% (SOX).
Conclusions
The trial showed perioperative C combined with R and chemo significantly improved pCR compared to chemo alone with a tolerable safety profile for localized resectable G/GEJ adenocarcinoma.
Clinical trial identification
NCT04208347.
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
554MO - Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial
- Gong Chen (Guangzhou, China)
Abstract
Background
The TRICE study was designed to determine whether intensifying the chemotherapy backbone in cetuximab-containing regimens could confer additional clinical benefits to RAS wild-type colorectal cancer (CRC) patients with initially unresectable liver metastases.
Methods
Patients were randomly assigned to receive either cetuximab plus FOLFOXIRI (triplet arm) or cetuximab plus FOLFOX (doublet arm) every 2 weeks. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least one line of chemotherapy. The primary end point was the objective response rate (ORR). Secondary end points included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.
Results
From January 2018 to December 2022, 146 patients were randomized to the cetuximab plus FOLFOXIRI (n = 72) or the cetuximab plus FOLFOX (n = 74) treatment arms. The ORR was comparable with 84.7% versus 79.7% in the triplet and doublet arms, respectively (OR = 0.71, 95% CI 0.30 to 1.67; P = .43). Although intensifying the chemotherapy backbone led to a higher median DpR (59.6% vs. 55.0%; P = .039), other secondary outcomes remained comparable between the two arms. At a median follow-up of 26.2 months, the median PFS was 11.7 months in the triplet arm vs. 13.4 months in the doublet arm (HR = 1.37, 95% CI 0.91 to 2.07; P = .13). Additionally, the triplet arm was associated with a higher incidence of grade 3-4 neutropenia (44.1% vs. 27.0%; P = .03) and diarrhea (5.9% vs. 0%; P = .03).
Conclusions
Although intensifying upfront systemic chemotherapy in RAS wild-type metastatic CRC patients offered a better depth of tumor response, there was an increase in neutropenia and diarrhea incidence with no significant difference in ORR, PFS, and R0 resection rate.
Clinical trial identification
NCT03493048.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
239MO - Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
- Haizhu Chen (Beijing, China)
Abstract
Background
The relationships between body mass index (BMI) and survival outcomes are complex, and have not been thoroughly investigated in breast cancer patients who received adjuvant chemotherapy.
Methods
We collected data on 2394 patients from two randomized, phase III clinical trials that investigated adjuvant chemotherapy in breast cancer identified in Project Data Sphere. The objective was to examine the effect of baseline BMI, BMI after adjuvant chemotherapy, and BMI change from baseline to post-adjuvant chemotherapy on disease-free survival (DFS) and overall survival (OS). Restricted cubic splines, adjusting for confounding factors, were used to examine potential non-linear associations between continuous BMI value and survival. Stratified analyses involved chemotherapy regimens used.
Results
On multivariate analysis, severe obesity (BMI≥40.0 kg/m2) at baseline was independently associated with worse DFS (HR=1.48, 95%CI 1.02-2.16,
Conclusions
In early breast cancer patients treated with adjuvant chemotherapy, baseline severe obesity was lined to worse DFS and OS, while a BMI loss over 10% from baseline to post-adjuvant chemotherapy also negatively affected OS. Moreover, the prognostic role of BMI might differ between docetaxel-based and non-docetaxel-based groups.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Multi-facets of antiangiogenic agents
- Tom Wei-Wu Chen (Taipei City, Taiwan)
1593MO - Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China
- Mengting Chen (Chongqing, China)
Abstract
Background
Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care (based on Ewarm model) for patients with NSCLC on the quality of life (QoL), psychological state, cancer pain and nutritional status.
Methods
In this randomised controlled trial, 280 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary end point was overall survival (OS). The second end point was the change in the quality of life, psychological state, pain and nutritional status at 24 weeks. Analysis was by intention to treat.
Results
280 patients were enrolled: 140 in CEPC group (102 completed) and 140 in the SC group (82 completed). CEPC group had a better QoL than SC group (all
Conclusions
Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in longer survival, quality of life, psychological state, pain and nutritional status.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.